Dharm S. Patel
YOU?
Author Swipe
Patient-reported outcome assessment of adults and adolescents with atopic dermatitis: a cross-sectional qualitative interview study Open
Background Atopic dermatitis (AD) is a chronic inflammatory skin disease that impacts patient health and quality of life. Understanding patient experience of relevant symptoms and impacts of AD is crucial for improving outcomes. This study…
Cholecysto - Duodenal Fistula with GI Obstruction and Perforation: A Rare Case Report Open
The Gastrointestinal obstruction (rarely GI perforation) is a serious complication of cholelithiasis due to the formation of a fistula from the gallbladder to the subjacent duodenum. The gallstones are usually large enough to cause intesti…
Qualitative concept elicitation and cognitive debriefing interviews of symptoms, impacts and selected customized PROMIS® Short Forms: a study in patients with axial spondyloarthritis Open
Background Sleep disturbance, pain, and fatigue are key symptoms/impacts of axial spondyloarthritis (axSpA). Three customized Patient-Reported Outcomes Measurement Information System (PROMIS ® ) Short Forms (Sleep Disturbance, Pain Interfe…
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641–649 Open
This article responds to:Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-ad…
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis Open
Pooled data analysis showed that the PGA×BSA and mPASI correlation was higher with increasing psoriasis severity.
Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study. Open
BACKGROUND: There are a variety of treatment options currently available for plaque psoriasis affecting the scalp, yet scalp psoriasis remains one of the most frustrating and difficult-to-manage forms of the disease. OBJECTIVE: We investig…
Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis Open
Background: The fixed-dose combination foam formulation of calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) has demonstrated efficacy and a favorable safety profile for the treatment of plaque psoriasis. Recently, a top…
Calcipotriene plus betamethasone dipropionate (0.005%/0.064%) foam and apremilast: matching-adjusted indirect comparison and US cost per responder analyses Open
not available. Disclosures: Study sponsored by LEO Pharma. Copyright 2018 SKIN
DNA repair and cell cycle checkpoint defects in a mouse model of ‘BRCAness’ are partially rescued by 53BP1 deletion Open
‘BRCAness’ is a term used to describe cancer cells that behave similarly to tumors with BRCA1 or BRCA2 mutations. The BRCAness phenotype is associated with hypersensitivity to chemotherapy agents including PARP inhibitors, which are a prom…
Patient Preferences for Vehicle and Overall Preference of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam and Gel in the PSO-INSIGHTFUL Study Open
not available. Disclosures: Study sponsored by Leo Pharma. Copyright 2018 SKIN
BLM helicase regulates DNA repair by counteracting RAD51 loading at DNA double-strand break sites Open
The BLM gene product, BLM, is a RECQ helicase that is involved in DNA replication and repair of DNA double-strand breaks by the homologous recombination (HR) pathway. During HR, BLM has both pro- and anti-recombinogenic activities, either …
The bloom syndrome protein, BLM, inhibits homologous recombination by disrupting RAD51 nucleoprotein filaments Open
BRCA1-deficient cells exhibit increased genomic instability following DNA damaging treatments due to a defect in the homologous recombination (HR) DNA repair pathway. Here, we show that the Bloom Syndrome Protein, BLM, mediates the genomic…